Esam Hamad Alhamad, Joseph Galindo Cal, Ahmad Amer AlBoukai, Shaffi Ahmed Shaik, Mohammed Ahmed Omair
BACKGROUND AND AIMS: Information regarding autoimmune symptoms that do not meet the diagnostic criteria for connective tissue disease in patients with idiopathic pulmonary fibrosis (IPF) is limited. The aim of the present study was to investigate differences in the clinical characteristics and prognosis of IPF patients with and without autoimmune symptoms. METHODS: Consecutive patients diagnosed with IPF (N = 96) from January 2008 to December 2012 were included...
May 2016: Clinical Respiratory Journal
Ivana V Yang, Brent S Pedersen, Einat Rabinovich, Corinne E Hennessy, Elizabeth J Davidson, Elissa Murphy, Brenda Juan Guardela, John R Tedrow, Yingze Zhang, Mandal K Singh, Mick Correll, Marvin I Schwarz, Mark Geraci, Frank C Sciurba, John Quackenbush, Avrum Spira, Naftali Kaminski, David A Schwartz
RATIONALE: Idiopathic pulmonary fibrosis (IPF) is an untreatable and often fatal lung disease that is increasing in prevalence and is caused by complex interactions between genetic and environmental factors. Epigenetic mechanisms control gene expression and are likely to regulate the IPF transcriptome. OBJECTIVES: To identify methylation marks that modify gene expression in IPF lung. METHODS: We assessed DNA methylation (comprehensive high-throughput arrays for relative methylation arrays [CHARM]) and gene expression (Agilent gene expression arrays) in 94 patients with IPF and 67 control subjects, and performed integrative genomic analyses to define methylation-gene expression relationships in IPF lung...
December 1, 2014: American Journal of Respiratory and Critical Care Medicine
T Kurita, S Yasuda, O Amengual, T Atsumi
Interstitial lung disease (ILD) in patients with polymyositis (PM) and dermatomyositis (DM) is often resistant to treatment and life threatening, being recognized as one of the severest complication in these autoimmune disorders. Patients with clinically amyopathic dermatomyositis (CADM) or those with anti-CADM140/MDA5 antibody are especially prone to develop rapidly progressive interstitial pneumonia. We retrospectively analyzed 46 patients with PM/DM admitted to our hospital and identified DM, rapidly progressive disease, honeycomb lung, CADM and extensive ILD as risk factors for recurrence or death...
January 2015: Lupus
Nicoline M Korthagen, Coline H M van Moorsel, Pieter Zanen, Henk J Ruven, Jan C Grutters
INTRODUCTION: YKL-40 is a novel biomarker in diseases with inflammation, fibrosis and tissue remodelling. Previously, circulating YKL-40 was shown to be elevated in patients with idiopathic pulmonary fibrosis (IPF) and was associated with survival. OBJECTIVE: To compare YKL-40 serum levels between IPF and other interstitial pneumonias such as non-specific interstitial pneumonia (NSIP), smoking-related interstitial lung disease (SR-ILD) and cryptogenic organising pneumonia (COP)...
December 2014: Lung
Daryle J DePianto, Sanjay Chandriani, Alexander R Abbas, Guiquan Jia, Elsa N N'Diaye, Patrick Caplazi, Steven E Kauder, Sabyasachi Biswas, Satyajit K Karnik, Connie Ha, Zora Modrusan, Michael A Matthay, Jasleen Kukreja, Harold R Collard, Jackson G Egen, Paul J Wolters, Joseph R Arron
BACKGROUND: There is microscopic spatial and temporal heterogeneity of pathological changes in idiopathic pulmonary fibrosis (IPF) lung tissue, which may relate to heterogeneity in pathophysiological mediators of disease and clinical progression. We assessed relationships between gene expression patterns, pathological features, and systemic biomarkers to identify biomarkers that reflect the aggregate disease burden in patients with IPF. METHODS: Gene expression microarrays (N=40 IPF; 8 controls) and immunohistochemical analyses (N=22 IPF; 8 controls) of lung biopsies...
January 2015: Thorax
Steven K Huang, Anne M Scruggs, Richard C McEachin, Eric S White, Marc Peters-Golden
Excessive fibroproliferation is a central hallmark of idiopathic pulmonary fibrosis (IPF), a chronic, progressive disorder that results in impaired gas exchange and respiratory failure. Fibroblasts are the key effector cells in IPF, and aberrant expression of multiple genes contributes to their excessive fibroproliferative phenotype. DNA methylation changes are critical to the development of many diseases, but the DNA methylome of IPF fibroblasts has never been characterized. Here, we utilized the HumanMethylation 27 array, which assays the DNA methylation level of 27,568 CpG sites across the genome, to compare the DNA methylation patterns of IPF fibroblasts (n = 6) with those of nonfibrotic patient controls (n = 3) and commercially available normal lung fibroblast cell lines (n = 3)...
2014: PloS One
Joseph D Zibrak, David Price
Interstitial lung disease (ILD) describes a group of diseases that cause progressive scarring of the lung tissue through inflammation and fibrosis. The most common form of ILD is idiopathic pulmonary fibrosis, which has a poor prognosis. ILD is rare and mainly a disease of the middle-aged and elderly. The symptoms of ILD-chronic dyspnoea and cough-are easily confused with the symptoms of more common diseases, particularly chronic obstructive pulmonary disease and heart failure. ILD is infrequently seen in primary care and a precise diagnosis of these disorders can be challenging for physicians who rarely encounter them...
September 11, 2014: NPJ Primary Care Respiratory Medicine
Déborah François, Laurence Venisse, Joëlle Marchal-Somme, Martine Jandrot-Perrus, Bruno Crestani, Véronique Arocas, Marie-Christine Bouton
Idiopathic pulmonary fibrosis (IPF) is a chronic diffuse lung disease characterized by an accumulation of excess fibrous material in the lung. Protease nexin-1 (PN-1) is a tissue serpin produced by many cell types, including lung fibroblasts. PN-1 is capable of regulating proteases of both coagulation and fibrinolysis systems, by inhibiting, respectively, thrombin and plasminergic enzymes. PN-1 is thus a good candidate for regulating tissue remodeling occurring during IPF. We demonstrated a significant increase of PN-1 expression in lung tissue extracts, lung fibroblasts and bronchoalveolar lavage fluids of patients with IPF...
November 2014: Laboratory Investigation; a Journal of Technical Methods and Pathology
Jordan R Covvey, Erin E Mancl
OBJECTIVE: To describe emerging evidence for the pharmacological treatment of idiopathic pulmonary fibrosis (IPF). DATA SOURCES: A search of PubMed (1966 to July 2014) was performed using the terms idiopathic pulmonary fibrosis and treatment. STUDY SELECTION AND DATA EXTRACTION: Review of articles was restricted to articles in English and relating to placebo-controlled or comparative clinical trial data of recent significance. Evidence statements from the most recent international guidelines and some historical trial data were also included for context...
December 2014: Annals of Pharmacotherapy
Mehrdad Bakhshayesh Karam, Hamideh Peivareh, Leila Mosadegh
BACKGROUND: Collagen vascular diseases (CVDs) are well known causes of pulmonary involvement, leading to significant morbidity. The purpose of this study was to identify several thoracic computed tomographic findings of CVDs. MATERIALS AND METHODS: The study included 56 patients (15 males and 41 females) with histopathologically and clinically proven CVDs who were identified retrospectively. The presence, extent and distribution of various CT findings were evaluated by a radiologist...
2014: Tanaffos
Akash Kumar, Max Dougherty, Gregory M Findlay, Madeleine Geisheker, Jason Klein, John Lazar, Heather Machkovech, Jesse Resnick, Rebecca Resnick, Alexander I Salter, Faezeh Talebi-Liasi, Christopher Arakawa, Jacob Baudin, Andrew Bogaard, Rebecca Salesky, Qian Zhou, Kelly Smith, John I Clark, Jay Shendure, Marshall S Horwitz
Even in cases where there is no obvious family history of disease, genome sequencing may contribute to clinical diagnosis and management. Clinical application of the genome has not yet become routine, however, in part because physicians are still learning how best to utilize such information. As an educational research exercise performed in conjunction with our medical school human anatomy course, we explored the potential utility of determining the whole genome sequence of a patient who had died following a clinical diagnosis of idiopathic pulmonary fibrosis (IPF)...
2014: PloS One
Thomas Colby
Neither the pathologist nor the radiologist makes the diagnosis of IPF. It is a clinical diagnosis. Current recommendations are that the diagnosis of IPF follows multidisciplinary discussion (MDD) involving clinicians, radiologists and, if tissue is take, pathologists. According to the 2011 IPF guidelines, the diagnosis of IPF requires the pathologic and/or radiologic pattern of usual interstitial pneumonia (UIP) on surgical lung biopsy or HRCT respectively.IPF represents UIP of unknown cause. UIP ≠ IPF. There are other causes of UIP including chronic hypersensitivity pneumonitis, connective tissue diseases, familial pulmonary fibrosis, some drug reactions and miscellaneous rare conditions...
October 2014: Pathology
Andrew G Nicholson
This presentation reviews the histopathology of the IIPs since the 2002 ATS/ERS classification of IIPs in the light of the 2013 update. The seven histological patterns proposed in 2002 remain, with diagnostic criteria refined but overall unchanged. A multidisciplinary approach is now established as best practice. NSIP is now recognised as a distinct clinicopathological entity. Respiratory bronchiolitis-interstitial lung disease (RB-ILD) is now commonly diagnosed without the need for surgical biopsy. A diagnostic algorithm has been proposed for the correlation of surgical biopsies with imaging in relation to patients with suspected idiopathic pulmonary fibrosis (IPF)...
October 2014: Pathology
A Whitney Brown, Chelsea P Fischer, Oksana A Shlobin, Russell G Buhr, Shahzad Ahmad, Nargues A Weir, Steven D Nathan
OBJECTIVE: The outcomes of patients with idiopathic pulmonary fibrosis (IPF) who undergo hospitalization have not been well characterized. We sought to determine the frequency of all-cause and respiratory-related hospitalizations and to evaluate their impact on the subsequent course and survival of patients with IPF. METHODS: The records of patients with IPF evaluated at a tertiary center were examined for the cause and duration of hospitalization. Data on subsequent patient outcomes were collated...
January 2015: Chest
Kathleen O Lindell, Zhan Liang, Leslie A Hoffman, Margaret Q Rosenzweig, Melissa I Saul, Joseph M Pilewski, Kevin F Gibson, Naftali Kaminski
BACKGROUND: Palliative care, integrated early, may reduce symptom burden in patients with idiopathic pulmonary fibrosis (IPF). However, limited information exists on timing and clinical practice. The purpose of this study was to describe the time course of events prior to death in patients with IPF managed at a specialty center with a focus on location of death and timing of referral for palliative care. METHODS: Data were retrospectively extracted from the health system's data repository and obituary listings...
February 2015: Chest
Phillip L Molyneaux, Michael J Cox, Saffron A G Willis-Owen, Patrick Mallia, Kirsty E Russell, Anne-Marie Russell, Elissa Murphy, Sebastian L Johnston, David A Schwartz, Athol U Wells, William O C Cookson, Toby M Maher, Miriam F Moffatt
RATIONALE: Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease of unknown cause that leads to respiratory failure and death within 5 years of diagnosis. Overt respiratory infection and immunosuppression carry a high morbidity and mortality, and polymorphisms in genes related to epithelial integrity and host defense predispose to IPF. OBJECTIVES: To investigate the role of bacteria in the pathogenesis and progression of IPF. METHODS: We prospectively enrolled patients diagnosed with IPF according to international criteria together with healthy smokers, nonsmokers, and subjects with moderate chronic obstructive pulmonary disease as control subjects...
October 15, 2014: American Journal of Respiratory and Critical Care Medicine
Keishi Oda, Hiroshi Ishimoto, Sohsuke Yamada, Hisako Kushima, Hiroshi Ishii, Tomotoshi Imanaga, Tatsuhiko Harada, Yuji Ishimatsu, Nobuhiro Matsumoto, Keisuke Naito, Kazuhiro Yatera, Masamitsu Nakazato, Jun-Ichi Kadota, Kentaro Watanabe, Shigeru Kohno, Hiroshi Mukae
BACKGROUND: Acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) is associated with high mortality. However, few studies have so far reviewed analyses of autopsy findings in patients with AE-IPF. METHODS: We retrospectively reviewed 52 consecutive patients with AE-IPF who underwent autopsies at five university hospitals and one municipal hospital between 1999 and 2013. The following variables were abstracted from the medical records: demographic and clinical data, autopsy findings and complications during the clinical course until death...
September 1, 2014: Respiratory Research
Claudia Landi, Elena Bargagli, Alfonso Carleo, Laura Bianchi, Assunta Gagliardi, Antje Prasse, Maria G Perari, Rosa M Refini, Luca Bini, Paola Rottoli
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) is a devastating interstitial lung disease characterized by progressive loss of the alveolar integrity, recruitment, and activation of myofibroblast, and excessive collagen deposition that resulted in loss of parenchymal architecture and lung function. Although etiology is unknown, major risk factor of disease development is represented by cigarette smoke or exposure to dust. AIMS: Aim of this proteomic study was to compare broncho alveolar lavage fluid protein profiles of IPF patients, never-smoker healthy control (nonsmoker control) and smoker control subjects in order to investigate proteins potentially related to disease progression and pathogenesis...
December 2014: Proteomics. Clinical Applications
Thanh-Thuy T Le, Harry Karmouty-Quintana, Ernestina Melicoff, Thanh-Truc T Le, Tingting Weng, Ning-Yuan Chen, Mesias Pedroza, Yang Zhou, Jonathan Davies, Kemly Philip, Jose Molina, Fayong Luo, Anuh T George, Luis J Garcia-Morales, Raquel R Bunge, Brian A Bruckner, Matthias Loebe, Harish Seethamraju, Sandeep K Agarwal, Michael R Blackburn
Idiopathic pulmonary fibrosis (IPF) is a lethal lung disease with progressive fibrosis and death within 2-3 y of diagnosis. IPF incidence and prevalence rates are increasing annually with few effective treatments available. Inhibition of IL-6 results in the attenuation of pulmonary fibrosis in mice. It is unclear whether this is due to blockade of classical signaling, mediated by membrane-bound IL-6Rα, or trans signaling, mediated by soluble IL-6Rα (sIL-6Rα). Our study assessed the role of sIL-6Rα in IPF...
October 1, 2014: Journal of Immunology: Official Journal of the American Association of Immunologists
Poornima Mahavadi, Ingrid Henneke, Clemens Ruppert, Lars Knudsen, Shalini Venkatesan, Gerhard Liebisch, Rachel C Chambers, Matthias Ochs, Gerd Schmitz, Carlo Vancheri, Werner Seeger, Martina Korfei, Andreas Guenther
Amiodarone (AD) is a highly efficient antiarrhythmic drug with potentially serious side effects. Severe pulmonary toxicity is reported in patients receiving AD even at low doses and may cause interstitial pneumonia as well as lung fibrosis. Apoptosis of alveolar epithelial type II cells (AECII) has been suggested to play an important role in this disease. In the current study, we aimed to establish a murine model of AD-induced lung fibrosis and analyze surfactant homeostasis, lysosomal, and endoplasmic reticulum (ER) stress in this model...
November 2014: Toxicological Sciences: An Official Journal of the Society of Toxicology
2014-08-30 19:17:55
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"